Company Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2023-12-05 pm EST Intraday chart for Gilead Sciences, Inc. 5-day change 1st Jan Change
79.02 USD +0.87% +6.05% -7.96%

Business Summary

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Number of employees : 17,000

Sales per Business

USD in Million2021Weight2022Weight Delta
Innovative Medicines
100.0 %
27,305 100.0 % 27,281 100.0 % -0.09%

Sales per region

USD in Million2021Weight2022Weight Delta
United States
69.2 %
19,267 70.6 % 18,884 69.2 % -1.99%
Europe
16.4 %
4,874 17.9 % 4,469 16.4 % -8.31%
Other International
14.4 %
3,164 11.6 % 3,928 14.4 % +24.15%

Managers

Managers TitleAgeSince
Chief Executive Officer 58 2019
Director of Finance/CFO 53 2015
Chief Tech/Sci/R&D Officer - 2021
Chief Tech/Sci/R&D Officer 60 2019
Investor Relations Contact - 2020
Corporate Officer/Principal 49 2020
Corporate Officer/Principal - -
Corporate Officer/Principal 53 2022
Corporate Officer/Principal - 2020
Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 68 2020
Director/Board Member 70 2017
Director/Board Member 68 2009
Director/Board Member 69 2018
Director/Board Member 52 2020
Chief Executive Officer 58 2019
Director/Board Member 74 2020
Director/Board Member 55 2016
Director/Board Member 69 2020

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,246,041,895 1,244,607,836 ( 99.88 %) 0 99.88 %

Shareholders

NameEquities%Valuation
The Vanguard Group, Inc.
8.629 %
107,519,953 8.629 % 8 445 M $
Capital Research & Management Co. (World Investors)
6.824 %
85,024,189 6.824 % 6 678 M $
Capital Research & Management Co. (Global Investors)
3.318 %
41,348,459 3.318 % 3 248 M $
Dodge & Cox
2.200 %
27,411,892 2.200 % 2 153 M $
Geode Capital Management LLC
1.807 %
22,511,915 1.807 % 1 768 M $
Fidelity Management & Research Co. LLC
1.385 %
17,256,433 1.385 % 1 355 M $
Wellington Management Co. LLP
1.128 %
14,061,052 1.128 % 1 104 M $
Norges Bank Investment Management
1.043 %
12,989,938 1.043 % 1 020 M $
Capital International Ltd.
0.8633 %
10,756,580 0.8633 % 845 M $
Parnassus Investments LLC
0.8619 %
10,739,410 0.8619 % 843 M $
NameEquities%Valuation
Bram Bradesco Asset Management S/A DTVM
0.000294 %
7,330 0.000294 % 285 002 $
BB Gestão de Recursos DTVM SA
0.000284 %
7,086 0.000284 % 275 515 $
Western Asset Management Company DTVM Ltda.
0.000101 %
2,516 0.000101 % 97 826 $

Holdings

NameEquities%Valuation
16,707,477 25.35% 551,515,654 $
13,073,668 24.84% 11,465,607 $
14,823,029 19.90% 232,869,786 $
16,635,286 14.61% 24,952,929 $
3,478,261 7.19% 122,608,700 $
2,931,467 6.69% 11,813,812 $
4,854,443 4.77% 40,777,321 $
3,759,465 4.61% 1,624,089 $

Company contact information

Gilead Sciences, Inc.

333 Lakeside Drive

94404, Foster City

+650 574 3000

http://www.gilead.com
address Gilead Sciences, Inc.(GILD)

Group companies

NameCategory and Sector
Gilead Sciences Ireland UC
-
Gilead Therapeutics A1 Unlimited Co.
Health Technology - Pharmaceuticals: Major

Sales per region

Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
79.02USD
Average target price
90.39USD
Spread / Average Target
+14.39%
Consensus
1st Jan change Capi.
-7.96% 97 615 M $
+60.77% 527 B $
+46.50% 448 B $
-10.25% 382 B $
-4.25% 266 B $
-10.54% 255 B $
-13.61% 227 B $
+1.76% 203 B $
-9.57% 201 B $
-43.23% 165 B $
Other Pharmaceuticals
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer